source
- Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firmsSofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
- BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 RankingSTAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…